Milestone Pharmaceuticals Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Milestone Pharmaceuticals Inc. stock issued during period, value, new issues for the quarter ending 2026-06-30 was -$1.00K.
- Milestone Pharmaceuticals Inc. stock issued during period, value, new issues for the quarter ending 2026-03-31 was $10.89M.
- Milestone Pharmaceuticals Inc. stock issued during period, value, new issues for the quarter ending 2025-12-31 was $14.44M.
- Milestone Pharmaceuticals Inc. stock issued during period, value, new issues for the quarter ending 2025-09-30 was $23.14M.
- Milestone Pharmaceuticals Inc. stock issued during period, value, new issues for fiscal 2025 was $37.59M, a 37.89% increase from fiscal 2024.
- Milestone Pharmaceuticals Inc. stock issued during period, value, new issues for fiscal 2024 was $27.26M.
- Milestone Pharmaceuticals Inc. stock issued during period, value, new issues for fiscal 2022 was $2.63M.
- Milestone Pharmaceuticals Inc. stock issued during period, value, new issues for fiscal 2020 was $48.15M, a 43.59% decline from fiscal 2019.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-06-30 | -$1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $48.48M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $10.89M 10-Q · filed 2026-05-13 | |
| 2025-12-31 | $14.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-20 | $37.59M 10-K · filed 2026-03-20 |
| 2025-09-30 | $23.14M 10-Q · filed 2025-11-12 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-20 | $27.26M 10-K · filed 2026-03-20 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | |
| 2024-03-31 | $27.26M 10-Q · filed 2025-05-14 | |
| 2022-12-31 | -$14.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $2.63M 10-K · filed 2024-03-21 |
| 2022-09-30 | $2.64M 10-Q · filed 2023-11-13 | |
| 2020-12-31 | $48.15M 10-K · filed 2022-03-24 | |
| 2019-12-31 | $85.36M 10-K · filed 2021-03-29 | |
| 2019-06-30 | $85.36M 10-Q · filed 2020-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B |